Innovating for Louisiana's Future


Investigators at the LSU Health Sciences Centers in New Orleans and Shreveport create and disseminate knowledge through basic, clinical, and translational research. In the course of this research, inventions may arise; commercialization of these inventions through a process called “technology transfer” further supports the academic mission and increases the potential for economic impact. Technology transfer offices at the two LSU Health Sciences Centers advance innovation by serving the faculty, supporting the research enterprise, and partnering with entrepreneurs and businesses to commercialize inventions that enhance the economy and benefit the public.


Combined Research Impact and Outcomes

Over the last 15 years, nearly $1.2 billion dollars in research has generated:

  • Nearly 500 new inventions

  • Over 250 new patents

  • 60 license agreements to commercialize inventions

  • 15 new start-up companies


inno2Three LSU Health New Orleans investigators developed a novel approach to treat or prevent acne using topical botulinum toxin (better known under the brand name Botox™). In 2008, this invention, by Drs. Ann Tilton, Dana Suskind and Mary Caire, was licensed to Anterios, a small clinical stage pharmaceutical company. Recently, this company, along with LSU Health New Orleans' rights to the invention, was acquired by Allergan, the world's largest pharmaceutical company.



A group of novel pain-killers have been developed at LSU Health New Orleans by Dr. Nicolas Bazan, Director of the LSUHSC Neuroscience Center of Excellence. The portfolio of patents covering these new analgesic compounds were licensed for commercial development by Colby Pharmaceuticals. These new compounds are unique derivatives of acetaminophen (more commonly known by the brand name Tylenol®), but do not share its toxic effects in the liver.


inno4LSU Health New Orleans researchers Dr. Dennis Paul, Professor of Pharmacology, and Dr. Harry Gould, Professor of Neurology and Neuroscience, have founded a company - Oleander Medical Technologies - around a technology developed in their lab for a  process called Targeted Osmotic Lysis (TOL), which  destroys  cancer cells without damaging other cells in the body. These two entrepreneurial scientists hope this revolutionary new treatment will be able to target many of the most invasive and deadly cancers without causing many of the side effects typically associated with traditional cancer treatments.